School of Medicine Publications

Document Type

Article

Publication Date

2026

Abstract

Background and aims: Metabolic dysfunction-associated steatotic liver disease (MASLD) is increasingly recognized for its extrahepatic consequences, including emerging links to neurodegenerative disorders such as Alzheimer disease (AD). Whether AD mortality risk differs across MASLD phenotypes, remains unclear.

Methods: We analyzed adults from the Third National Health and Nutrition Examination Survey (1988-1994) with mortality follow-up through 2019 via the National Death Index. Participants were followed for AD mortality. Cumulative incidence was estimated using Kaplan-Meier methods. Cox proportional hazards models evaluated MASLD phenotypes and AD mortality, adjusting for age, sex, race/ethnicity, poverty-income ratio, body mass index, and smoking status.

Results: Among 7125 adults, 1033 had nonobese MASLD and 817 had obese MASLD. At baseline, nonobese MASLD participants were older (mean age 60 ± 12 years), more likely male (59%), and more frequently White (46%) compared with obese MASLD (mean age 56 ± 13 years, 46% male, 37% White; P < .001). Age-standardized cumulative incidence of AD mortality was highest in nonobese MASLD (1.98%), followed by non-MASLD (1.81%) and obese MASLD (0.78%). In adjusted models, MASLD was not significantly associated with AD mortality overall. However, nonobese MASLD was independently associated with higher AD mortality compared with obese MASLD (adjusted hazard ratio 3.76; 95% confidence interval 1.19, 11.90; P = .024) and with the overall population (adjusted hazard ratio 1.49; 95% confidence interval 1.03, 2.16; P = .034).

Conclusion: Nonobese MASLD emerged as distinct high-risk metabolic phenotype associated with significantly higher AD mortality, independent of demographic, socioeconomic, and behavioral factors. These findings suggest that nonobese MASLD may reflect unique neuro-metabolic vulnerability and warrant further mechanistic investigation into pathways such as differential adiposity patterns, inflammation, and metabolic signaling. Targeted screening, improved risk stratification, and prospective studies are needed to better define and mitigate long-term cognitive risks in this understudied subgroup.

Comments

© 2026 The Authors

This is an open access article under the CC BY license

Creative Commons License

Creative Commons Attribution 4.0 International License
This work is licensed under a Creative Commons Attribution 4.0 International License.

Publication Title

Gastro Hep Advances

DOI

10.1016/j.gastha.2026.101030

Academic Level

resident

Mentor/PI Department

Internal Medicine

Download

Share

COinS
 
 

To view the content in your browser, please download Adobe Reader or, alternately,
you may Download the file to your hard drive.

NOTE: The latest versions of Adobe Reader do not support viewing PDF files within Firefox on Mac OS and if you are using a modern (Intel) Mac, there is no official plugin for viewing PDF files within the browser window.